Role of psychiatric medications as adjunct therapy in the treatment of HIV associated neurocognitive disorders

References

• Ances BM, Letendre S, Buzzell M, et al. Valproic acid does not affect markers of human immunodeficiency virus disease progression. Journal of Neurovirology 2006; 12: 403–406
   PubMed Web of Science ®Google Scholar
• Atkinson JH, Slater MA, Wahlgren DR, et al. Effects of noradrenergic and serotonergic antidepressants on chronic low back pain intensity. Pain 1999; 83: 137–145
   PubMed Web of Science ®Google Scholar
• Baldessarini RJ, Leahy L, Arcona S, Gause D, Zhang W, Hennen J. Patterns of psychotropic drug prescription for US patients with diagnoses of bipolar disorders. Psychiatr Serv 2007; 58: 85–91
   PubMed Web of Science ®Google Scholar
• Cysique LA, Maruff P, Brew BJ. Antiretroviral therapy in HIV infection: Are neurologically active drugs important?. Arch Neurol 2004; 61: 1699–1704
   PubMedGoogle Scholar
• Dewhurst S, Maggirwar SB, Schifitto G, Gendelman HE, Gelbard HA. Glycogen synthase kinase 3 Beta (GSK-3beta) as a therapeutic target in neuroAIDS. Journal of Neuroimmune Pharmacology 2007; 2: 93–96
   PubMedGoogle Scholar
• Dou H, Ellison B, Bradley J, et al. Neuroprotective mechanisms of lithium in murine human immunodeficiency virus-1 encephalitis. Journal of Neuroscience 2005; 25: 8375–8385
   PubMed Web of Science ®Google Scholar
• Everall IP, Bell C, Mallory M, et al. Lithium ameliorates HIV-gp120-mediated neurotoxicity. Mol Cell Neurosci 2002; 21: 493–501
   PubMed Web of Science ®Google Scholar
• Gallicchio VS, Cibull ML, Hughes NK, Tse KF. Effect of lithium in murine immunodeficiency virus infected animals. Pathobiology 1993; 61: 216–221
   PubMed Web of Science ®Google Scholar
• Harvey BH, Meyer CL, Gallichio VS, Manji HK. Lithium salts in AIDS and AIDS-related dementia. Psychopharmacol Bull 2002; 36: 5–26
   PubMedGoogle Scholar
• Hashimoto M, Sagara Y, Langford D, et al. Fibroblast growth factor 1 regulates signaling via the glycogen synthase kinase-3beta pathway. Implications for neuroprotection. Journal of Biol Chem 2002; 277: 32985–32991
   PubMedGoogle Scholar
• Heaton RK, Marcotte TD, Mindt MR, et al. The impact of HIV-associated neuropsychological impairment on everyday functioning. Journal of the International Neuropsychological Society 2004; 10: 317–331
   PubMed Web of Science ®Google Scholar
• Kandanearatchi A, Vyakarnam A, Landau S, Everall IP. Suppression of human immunodeficiency virus replication in human brain tissue by nucleoside reverse transcriptase inhibitors. Journal of Neurovirology 2004; 10: 136–139
   PubMed Web of Science ®Google Scholar
• Kim AJ, Shi Y, Austin RC, Werstuck GH. Valproate protects cells from ER stress-induced lipid accumulation and apoptosis by inhibiting glycogen synthase kinase-3. Journal of Cell Science 2005; 18: 89–99
   Google Scholar
• Kristiansen JE, Hansen JB. Inhibition of HIV replication by neuroleptic agents and their potential use in HIV infected patients with AIDS related dementia. International Journal of Antimicrobial Agents 2000; 14: 209–213
   PubMedGoogle Scholar
• Lehrman G, Hogue IB, Palmer S, et al. Depletion of latent HIV-1 infection in vivo: A proof-of-concept study. Lancet 2005; 366: 549–555
   PubMed Web of Science ®Google Scholar
• Letendre SL, Marquie-Beck J, Ellis RJ, et al. The role of cohort studies in drug development: clinical evidence of antiviral activity of serotonin reuptake inhibitors and HMG-CoA reductase inhibitors in the central nervous system. Journal of Neuroimmune Pharmacology 2007; 2: 120–127
   PubMedGoogle Scholar
• Letendre SL, Woods SP, Ellis RJ, et al. Lithium improves HIV-associated neurocognitive impairment. AIDS 2006; 20: 1885–1888
   PubMed Web of Science ®Google Scholar
• Maggirwar SB, Tong N, Ramirez S, Gelbard HA, Dewhurst S. HIV-1 Tat-mediated activation of glycogen synthase kinase-3beta contributes to Tat-mediated neurotoxicity. Journal of Neurochemistry 1999; 73: 578–586
   PubMed Web of Science ®Google Scholar
• Manji HK, McNamara R, Chen G, Lenox RH. Signalling pathways in the brain: Xellular transduction of mood stabilisation in the treatment of manic-depressive illness. Australia & New Zealand Journal of Psychiatry 1999; 33: S65–S83
   Web of Science ®Google Scholar
• McArthur JC, Haughey N, Gartner S, et al. Human immunodeficiency virus-associated dementia: an evolving disease. Journal of Neurovirology 2003; 9: 205–221
   PubMed Web of Science ®Google Scholar
• Pieper AA, Treisman GJ. Drug treatment of depression in HIV-positive patients: Safety considerations. Drug Saf 2005; 28: 753–762
   PubMed Web of Science ®Google Scholar
• Sacktor N, McDermott MP, Marder K, et al. HIV-associated cognitive impairment before and after the advent of combination therapy. Journal of Neurovirology 2002; 8: 136–142
   PubMed Web of Science ®Google Scholar
• Schifitto G, Peterson DR, Zhong J, et al. Valproic acid adjunctive therapy for HIV-associated cognitive impairment: a first report. Neurology 2006; 66: 919–921
   PubMed Web of Science ®Google Scholar
• Taylor EM. The impact of efflux transporters in the brain on the development of drugs for CNS disorders. Clin Pharmacokinet 2002; 41: 81–92
   PubMed Web of Science ®Google Scholar
• Tozzi V, Balestra P, Lorenzini P, et al. Prevalence and risk factors for human immunodeficiency virus-associated neurocognitive impairment, 1996 to 2002: Results from an urban observational cohort. Journal of Neurovirology 2005; 11: 265–273
   PubMed Web of Science ®Google Scholar
• Wynn HE, Brundage RC, Fletcher CV. Clinical implications of CNS penetration of antiretroviral drugs. CNS Drugs 2002; 16: 595–609
   PubMed Web of Science ®Google Scholar
• Yasuda S, Liang MH, Marinova Z, Yahyavi A, Chuang DM. The mood stabilizers lithium and valproate selectively activate the promoter IV of brain-derived neurotrophic factor in neurons. Molecular Psychiatry 2007, epub ahead of print
   PubMedGoogle Scholar